Biosyent Inc. (CVE:RX) – Cormark issued their Q1 2017 EPS estimates for shares of Biosyent in a research note issued on Thursday. Cormark analyst D. Novak expects that the brokerage will earn $0.08 per share for the quarter. Cormark also issued estimates for Biosyent’s Q2 2017 earnings at $0.08 EPS, Q3 2017 earnings at $0.09 EPS, Q4 2017 earnings at $0.08 EPS and FY2017 earnings at $0.33 EPS.

COPYRIGHT VIOLATION WARNING: “Cormark Weighs in on Biosyent Inc.’s Q1 2017 Earnings (RX)” was first published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright law. The correct version of this story can be accessed at http://www.financial-market-news.com/cormark-weighs-in-on-biosyent-inc-s-q1-2017-earnings-rx/1210066/.

Earnings History and Estimates for Biosyent (CVE:RX)

COPYRIGHT VIOLATION WARNING: “Cormark Weighs in on Biosyent Inc.’s Q1 2017 Earnings (RX)” was first published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright law. The correct version of this story can be accessed at http://www.financial-market-news.com/cormark-weighs-in-on-biosyent-inc-s-q1-2017-earnings-rx/1210066/.

About Biosyent

BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Receive News & Ratings for Biosyent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.